PharmaShots Weekly Snapshots (March 31, 2025 – April 04, 2025)
This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & DigiHealth. Check out our full report below:
Eli Lilly Reports P-II (ALPACA) Trial Data of Lepodisiran for Heart Diseases
Read More: Eli Lilly
AstraZeneca Reports the Data from PURSUIT P-IIb Study Evaluating AZD0780
Read More: AstraZeneca
Axsome Therapeutics Reports Topline Data of P-III (PARADIGM) Trial of Solriamfetol for Major Depressive Disorder (MDD) regardless of Excessive Daytime Sleepiness (EDS)
Read More: Axsome Therapeutics
Daiichi Sankyo Reports the First Patient Dosing in P-III (DESTINY-Gastric05) Trial of Enhertu Regimen to Treat G/GEJ Cancer
Read More: Daiichi Sankyo
BridgeBio Oncology Therapeutics Reports the First Patient Dosing in P-I (KONQUER-101) Trial of BBO-11818 for Advanced Solid Tumors
Read More: BridgeBio Oncology Therapeutics
BMS’ Opdivo Receives the CHMP’s Positive Opinion as a Neoadjuvant Treatment of Resectable NSCLC
Read More: BMS
AstraZeneca’s Calquence (Acalabrutinib) Plus Chemoimmunotherapy Receives the CHMP’s Positive Opinion for 1L Mantle Cell Lymphoma (MCL)
Read More: AstraZeneca
Genmab and Pfizer Secure the EC’s Approval for Tivdak (Tisotumab Vedotin) for Recurrent or Metastatic Cervical Cancer
Read More: Genmab and Pfizer
Alnylam Pharmaceuticals and Sanofi Report the US FDA’s Approval of Qfitlia (Fitusiran) to Treat Hemophilia A or B
Read More: Alnylam Pharmaceuticals and Sanofi
Pfizer Secures the EC’s Approval for Abrysvo (Respiratory Syncytial Virus Vaccine) for RSV Lower Respiratory Tract Disease
Read More: Pfizer
Apellis Pharmaceuticals Reports the US FDA’s sNDA Acceptance & Priority Review of Empaveli for C3G and Primary IC-MPGN
Read More: Apellis Pharmaceuticals
Averoa Receives the CHMP’s Positive Opinion for Xoanacyl to Treat Chronic Kidney Disease
Read More: Averoa
Novartis’ Vanrafia (Atrasentan) Receives the US FDA’s Accelerated Approval for Primary IgA Nephropathy (IgAN)
Read More: Novartis
Amgen’s Uplizna Receives the US FDA’s Approval for Immunoglobulin G4-related Disease (IgG4-RD)
Read More: Amgen
Daiichi Sankyo and AstraZeneca Report the EC’s Approval of Enhertu for HER2 Low/Ultralow Metastatic Breast Cancer (MBC)
Read More: Daiichi Sankyo and AstraZeneca
AstraZeneca Reports the EC’s Approval of Imfinzi Regimen as Perioperative Treatment of NSCLC
Read More: AstraZeneca
Lexicon Enters a Global Licensing Agreement with Novo Nordisk for LX9851
Read More: Lexicon and Novo Nordisk
Ono Enters into an Option Agreement with Reborna Biosciences for RNA-Targeting Small Molecule to treat CNS Disorders
Read More: Ono and Reborna Biosciences
Sanofi Licenses an Undisclosed Nurix Therapeutics’ Drug Program for Autoimmune Diseases
Read More: Sanofi and Nurix Therapeutics
Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid
Read More: Eli Lilly and Sangamo Therapeutics
Visby Medical Reports the US FDA’s De Novo Authorization of its Women's Sexual Health Test for Over-the-Counter Use
Read More: Visby Medical
Echo IQ Enters into Strategic Partnership And Integration Agreements With ScImage And MedAxiom for EchoSolv AS
Read More: Echo IQ, ScImage and MedAxiom
The US FDA Grants 510(k) Clearance to Teleflex’s AC3 Range Intra-Aortic Balloon Pump (IABP) for Cardiac Patient Mobility
Read More: Teleflex
The US FDA Grants 510(k) Clearance to Medivis’ Spine Navigation Platform
Read More: Medivis
AVITA Medical Launches Cohealyx for Wound Healing in the US
Read More: AVITA Medical
Siemens to Acquire Dotmatics for $5.1B, Strengthening its Position in Life Science Market
Read More: Siemens and Dotmatics
Organon Acquires Regulatory and Commercial Rights of Tofidence IV Infusion (Biosimilar, Actemra) from Biogen in the US
Read More: Organon and Biogen
Accord Healthcare Reports the CHMP’s Positive Opinion on Osvyrti and Jubereq (Biosimilar, Prolia & Xgeva)
Read More: Accord Healthcare
Spirited Paw Launches Calm Chewable Wafers for Dogs and Cats
Read More: Spirited Paw
NetraMark Join Forces with Worldwide Clinical Trials to Redefine Clinical Trial Design Using NetraAI Platform
Read More: NetraMark and Worldwide Clinical Trials
Related Post: PharmaShots Weekly Snapshots (March 24, 2025 – March 28, 2025)
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
